These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 1971526)

  • 1. CD4-derived synthetic peptide blocks the binding of HIV-1 GP120 to CD4-bearing cells and prevents HIV-1 infection.
    Shapira-Nahor O; Golding H; Vujcic LK; Resto-Ruiz S; Fields RL; Robey FA
    Cell Immunol; 1990 Jun; 128(1):101-17. PubMed ID: 1971526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides.
    Batinić D; Robey FA
    J Biol Chem; 1992 Apr; 267(10):6664-71. PubMed ID: 1551875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a synthetic peptide that mimics an HIV glycoprotein 120 envelope conformational determinant exposed following ligation of glycoprotein 120 by CD4.
    Weinberg J; Liao HX; Torres JV; Matthews TJ; Robinson J; Haynes BF
    AIDS Res Hum Retroviruses; 1997 May; 13(8):657-64. PubMed ID: 9168234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.
    Peachman KK; Karasavvas N; Chenine AL; McLinden R; Rerks-Ngarm S; Jaranit K; Nitayaphan S; Pitisuttithum P; Tovanabutra S; Zolla-Pazner S; Michael NL; Kim JH; Alving CR; Rao M
    PLoS One; 2015; 10(12):e0143895. PubMed ID: 26625359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active immunity against the CD4 receptor by using an antibody antigenized with residues 41-55 of the first extracellular domain.
    Lanza P; Billetta R; Antonenko S; Zanetti M
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11683-7. PubMed ID: 8265609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence by peptide mapping that the region CD4(81-92) is involved in gp120/CD4 interaction leading to HIV infection and HIV-induced syncytium formation.
    Kalyanaraman VS; Rausch DM; Osborne J; Padgett M; Hwang KM; Lifson JD; Eiden LE
    J Immunol; 1990 Dec; 145(12):4072-8. PubMed ID: 1701782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short synthetic peptides derived from viral proteins compete with HIV gp120 for the binding to CD4 receptors.
    Chersi A; Pugliese O; Federico A; Viora M
    Viral Immunol; 2000; 13(4):547-54. PubMed ID: 11192301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic peptides representing discontinuous CD4 binding epitopes of HIV-1 gp120 that induce T cell apoptosis and block cell death induced by gp120.
    Howie SE; Cotton GJ; Heslop I; Martin NJ; Harrison DJ; Ramage R
    FASEB J; 1998 Aug; 12(11):991-8. PubMed ID: 9707171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal sequence requirements for synthetic peptides derived from the V3 loop of the human immunodeficiency virus type 1 (HIV-1) to enhance HIV-1 binding to cells and infection.
    Zanotto C; Calderazzo F; Dettin M; Di Bello C; Autiero M; Guardiola J; Chieco-Bianchi L; De Rossi A
    Virology; 1995 Feb; 206(2):807-16. PubMed ID: 7856094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multibranched peptide constructs derived from the V3 loop of envelope glycoprotein gp120 inhibit human immunodeficiency virus type 1 infection through interaction with CD4.
    Benjouad A; Chapuis F; Fenouillet E; Gluckman JC
    Virology; 1995 Jan; 206(1):457-64. PubMed ID: 7831801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms.
    Yahi N; Fantini J; Baghdiguian S; Mabrouk K; Tamalet C; Rochat H; Van Rietschoten J; Sabatier JM
    Proc Natl Acad Sci U S A; 1995 May; 92(11):4867-71. PubMed ID: 7761414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human immunodeficiency virus type 1 infection of SK-N-MC cells: domains of gp120 involved in entry into a CD4-negative, galactosyl ceramide/3' sulfo-galactosyl ceramide-positive cell line.
    Harouse JM; Collman RG; González-Scarano F
    J Virol; 1995 Dec; 69(12):7383-90. PubMed ID: 7494242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding to CD4 of synthetic peptides patterned on the principal neutralizing domain of the HIV-1 envelope protein.
    Autiero M; Abrescia P; Dettin M; Di Bello C; Guardiola J
    Virology; 1991 Dec; 185(2):820-8. PubMed ID: 1720590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HbAHP-25, an In-Silico Designed Peptide, Inhibits HIV-1 Entry by Blocking gp120 Binding to CD4 Receptor.
    Bashir T; Patgaonkar M; Kumar SC; Pasi A; Reddy KV
    PLoS One; 2015; 10(4):e0124839. PubMed ID: 25915507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells.
    Yahi N; Sabatier JM; Nickel P; Mabrouk K; Gonzalez-Scarano F; Fantini J
    J Biol Chem; 1994 Sep; 269(39):24349-53. PubMed ID: 7929093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor.
    Yuan W; Craig S; Si Z; Farzan M; Sodroski J
    J Virol; 2004 May; 78(10):5448-57. PubMed ID: 15113923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding.
    Healey D; Dianda L; Moore JP; McDougal JS; Moore MJ; Estess P; Buck D; Kwong PD; Beverley PC; Sattentau QJ
    J Exp Med; 1990 Oct; 172(4):1233-42. PubMed ID: 1698911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assays to detect and characterize human immunodeficiency virus type 1 (HIV-1) receptor antagonists, compounds that inhibit binding of the HIV-1 surface glycoprotein, gp120, to the CD4 receptor on human T lymphocytes.
    Clancy J; Tait-Kamradt A; Petitpas J; Manousos M; McGuirk PR; Subashi T; Watts P; Wondrack L
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2008-13. PubMed ID: 7811011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of V3 loop-binding proteins as potential receptors implicated in the binding of HIV particles to CD4(+) cells.
    Callebaut C; Blanco J; Benkirane N; Krust B; Jacotot E; Guichard G; Seddiki N; Svab J; Dam E; Muller S; Briand JP; Hovanessian AG
    J Biol Chem; 1998 Aug; 273(34):21988-97. PubMed ID: 9705340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple effects of CD4 CDR3-related peptide derivatives showing anti-HIV-1 activity on HIV-1 gp120 functions.
    Ohki K; Kimura T; Jones IM; Morita F; Ikuta K
    Vaccine; 1994 Mar; 12(4):343-50. PubMed ID: 8178557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.